Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology.
Despite awareness of the myriad IR-associated proatherogenic lipoprotein abnormalities (1-5,14-17), we are unaware of previous publications in which both IR and all relevant lipoproteins were quantified in the same cohort of individuals. This is likely partly attributable to the unavailability of analytical methods to measure multiple lipoprotein CHD risk factors in a clinically useful manner. However, the validated vertical auto profile-II (VAP-II) methodology (18) provides a means to comprehensively identify the IR-associated dyslipidemic profile, and we have used VAP-II to compare lipoprotein characteristics of nondiabetic individuals stratified into IR and insulin-sensitive (IS) groups.
The Stanford University Human Subjects Committee approved this study, and healthy volunteers from the San Francisco Bay Area gave informed consent. Participants underwent medical interview, anthropometric measurements, and a physical examination. Exclusion criteria included fasting plasma glucose >7.0 mmol/L (126 mg/ dL), total bilirubin >34 [micro]mol/L (2.0 mg/dL), serum albumin <30 g/L or creatinine >175 /,mol/L (2.0 mg/ dL), weight change >3.0 kg in 3 months, and active substance abuse. Results of a complete blood count, chemical screening battery, and electrocardiogram were normal in all participants.
Each participant underwent the insulin-suppression test, as introduced previously and validated by our group (19). Bilateral antecubital intravenous catheters were used for (a) 180-min infusion of octreotide acetate (0.27 [micro]g * [m-.sup.2] * [min.sup.-1]), insulin (32 mIU * [m.sup.-2] * [min.sup.- 1]), and glucose (267 Mg. [m.sup.-2] * [min.sup.-1]); and (b) collection of timed blood samples every 30 min initially, and then every 10 min from 150 to 180 min of the infusion. These last four time points were used to determine the steady-state plasma glucose (SSPG) and insulin (SSPI) concentrations. Because SSPI concentrations are similar among individuals, the SSPG concentration directly measures the ability of insulin to mediate disposal of an infused glucose load; higher SSPG values indicate increasing IR.
SSPG concentrations >10.8 mmol/L (195 mg/dL) were defined as IR, and SSPG <5.3 mmol/L (95 mg/dL) was defined as IS. These cut-points represent the SSPG values differentiating the upper and lower 30% of a population of >400 nondiabetic individuals that we tested previously (20). Using these criteria, we selected two groups: 23 IS and 21 IR individuals, none taking drugs known to affect blood pressure, glucose, or lipid metabolism. On a separate occasion, plasma glucose concentrations were determined before and 120 min after an oral 75-g glucose challenge.
Plasma samples obtained after an overnight fast were stored frozen at -70[degrees]C until lipoprotein analysis by the VAP-II method (18). VAP-II is a comprehensive lipoprotein profile testing method that directly measures cholesterol concentration in HDL,, HDL3, IDL, LDL, VLDL, and lipoprotein(a) [Lp(a)] in a single test. VAP-II has been extensively validated with the Lipid Research Clinics [beta]-quantification method performed at Northwest Lipid Research Laboratories at the University of Washington, Seattle, WA (18, 21). It should be emphasized that this method provides a specific measure of narrow-density LDL-C (ND-LDL-C), in contrast to the commonly measured LDL-C defined by the National Cholesterol Education Program, which includes both Lp(a) and IDL-C.
In VAP-II, the ND-LDL-C subclass pattern is further evaluated by determining the LDL peak maximum time, i.e., the relative position of the LDL peak in the density gradient on a relative scale of 0-200 s, with 0 s corresponding to the beginning of the HDL (the most dense lipoprotein) peak and 200 s corresponding to the VLDL (the least dense lipoprotein) peak maximum. Therefore, a patient with predominantly small, dense LDL has a lower LDL peak maximum time compared with the LDL peak maximum time of a patient with predominantly large, buoyant LDL. Thus, LDL pattern A (predominantly large and buoyant LDL subclass) is defined by a LDL maximum time >118 s, LDL pattern B by a LDL maximum time [less than or equal to]115 s, and intermediate pattern (A/B) by LDL maximum time >115 and [less than or equal to]118 s. Because the density and size of LDL are inversely related, we have compared VAP-II LDL peak maximum time (a function of density) with LDL size obtained by a commonly used 2-16% nondenaturing polyacrylamide gradient gel electrophoresis method performed at Pacific Biometrics Inc. (a CDC lipid-standardized laboratory), with a correlation coefficient of 0.832, and with the Nuclear Magnetic Resonance method performed at Liposcience Inc. (Raleigh, NC), with a correlation coefficient of 0.91 (unpublished data). VAP-II is based on use of a density gradient formed with 40-fold-diluted (40 [micro]L of original serum) and density-adjusted (1.21 kg/L) serum and 1.006 kg/L density saline in a centrifuge tube. The gradient is subjected to a single vertical spin density-gradient ultracentrifugation at 416 000g for 36 min, using the Beckman Optima-XL 100K ultracentrifuge. The separated lipoprotein classes and subclasses are then continuously drained from the bottom of the centrifuge tube into the VAP-II continuous flow analyzer, where they react sequentially with a cholesterol-specific enzymatic reagent, producing a concentration-dependent lipoprotein absorbance profile monitored by a spectrophotometer. The digital output of the spectrophotometer is also acquired by a computer and is further deconvoluted with use of in-house-developed software to provide cholesterol concentrations of individual lipoprotein classes and subclasses. The VAP is provided by Atherotech, Inc., a CDC-National Heart, Lung, and Blood Institute-standardized lipid laboratory.
Data are expressed as the mean (SE). The Student t-test and the [chi square] test were used to make comparisons between experimental groups. All statistical evaluations were performed with the SYSTAT 10.0 software package for Windows. Statistical significance was assigned at P <0.05.
The two experimental groups (IR and IS) were comparable in age [45 (2) vs 46 (3) years], gender distribution (11 males and 10 females vs 11 males and 12 females), and body mass index [28.5 (0.5) vs 28.6 (0.8) kg/[m.sup.2]]; all P >0.60. By selection, SSPG concentrations were higher in the IR group [13.1 (0.3) vs 4.0 (0.1) mmol/L; P <0.01]. Fasting and 120-min post-glucose load concentrations of glucose were also higher in the IR group [5.6 (0.1) vs 5.2 (0.1) and 7.2 (0.4) vs 4.9 (0.3) mmol/L; both P <0.01].
The VAP lipoprotein analysis is given in Table 1. The IR group had lower concentrations of both HDL subclasses, [HDL.sub.2] (P <0.001) and HDL, (P <0.001). Moreover, total TG concentrations were higher in the IR individuals (P <0.01), as were concentrations of all measured TG-rich lipoprotein classes, including IDL (P = 0.02); large, buoyant TG-rich [VLDL.sub.1 + 2] (P <0.01); and the small, dense cholesterol-rich [VLDL.sub.3a + 3b] (P <0.001). Although LDL-C appeared to be higher in the IR individuals (3.44 vs 3.24 mmol/L; P = 0.39), this effect was partially attributable to the effects of a significantly higher IDL (0.49 vs 0.39 mmol/L; P = 0.02) in the setting of almost identical Lp(a) concentrations (0.19 vs 0.18 mmol/L; P = 0.85). Consequently, the directly measured ND-LDL-C concentrations were similar in the two gro0ups (2.77 vs 2.67 mmol/L; P = 0.62). However, despite the similar concentrations of ND-LDL-C, the IR group had, on average, a small, denser LDL particle as indicated by a lower LDL maximum time (P <0.001), accompanied by a significantly higher proportion (P <0.001) of IR individuals identified with LDL pattern B (17 of 21) compared with IS individuals (4 of 23).
The results of this study demonstrate that IR individuals have increased concentrations of TG and various TG-rich lipoprotein cholesterol, decreased concentrations of both HDL subclasses, and a pattern of small, dense LDL. All of these lipoprotein patterns predispose to an increased risk of CHD (6-12). Although these findings have previously been reported separately to associate with the metabolic syndrome, they are not all routinely measured in assessing the impact of IR on lipoprotein metabolism. The importance of IR and its consequences have recently been emphasized by the report of the Adult Treatment Panel III outlining diagnostic criteria for identifying IR/hyperinsulinemic individuals with the metabolic syndrome (22). Because ~25% of the US population appears to have the metabolic syndrome as defined by the suggested criteria (23), it is of obvious importance to understand the relationship between the various components of IR and CHD. Although abnormal lipoprotein metabolism in the metabolic syndrome clearly contributes to CHD risk, the precise roles played by any particular member of the IR-associated atherogenic profile remain unclear (Table 1). The ability to quantify all such lipoprotein variables would help to further elucidate these complex relationships.
In conclusion, our results demonstrate that multiple abnormalities in lipoprotein metabolism constitute the atherogenic lipoprotein profile present in nondiabetic IR individuals. The VAP-II method provides a relatively simple approach to identifying all such components in an individual. The application of VAP-11 may be useful not only in elucidating the roles played by specific lipoprotein abnormalities in contributing to CHD, but also in yielding valuable insight into the specific benefits of therapeutic regimens to decrease CHD risk.
This work was supported by National Institutes of Health Grants HL07708 (to J.W.C.) and M01-RR070.
(1.) Reaven GM. Banting Lecture. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
(2.) Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992;231:25-30.
(3.) Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-6.
(4.) Jeppesen J, Hollenbeck CB, Zhou MY, Coulston AM, Jones C, Chen YD, et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995;15:320-4.
(5.) Ostlund RE Jr, Staten M, Kohrt WM, Schultz J, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl J Med 1990;322:229-34.
(6.) Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.
(7.) Brunner D, Weisbort J, Meshulam N, Schwartz S, Gross J, Saltz-Rennert H, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987;59:1271-6.
(8.) Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur HeartJ 1998;19:H31-6.
(9.) Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987;113:578-82.
(10.) Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16: 697-704.
(11.) Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-9.
(12.) LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997;157:961-8.
(13.) Cohn JS. Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins. Can J Cardiol 1998;14:18B-27B.
(14.) Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447-59.
(15.) Kim HS, Abbasi F, Lamendola C, McLaughlin T, Reaven GM. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. Am J Clin Nutr 2001;74:592-5.
(16.) Bavenholm P, Karpe F, Proudler A, Tornvall P, Crook D, Hamsten A. Association of insulin and insulin propeptides with an atherogenic lipoprotein phenotype. Metabolism 1995;44:1481-8.
(17.) Ai M, Tanaka A, Ogita K, Sekine M, Numano F, Numano F, et al. Relationship between hyperinsulinemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2000;85: 3557-60.
(18.) Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994;35:159-68.
(19.) Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970;49:2151-60.
(20.) Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000;23:171-5.
(21.) Kulkarni KR, Marcovina SM, Krauss RM, Garber DW, Glasscock AM, Segrest JP. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-11 (VAP-II) methodology. J Lipid Res 1997;38:2353-64.
(22.) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
(23.) Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
James W. Chu, (1) Fahim Abbasi, (1) Krishnaji R. Kulkarni, (2) Cynthia Lamendola, (1) Tracey L. McLaughlin, (1) Janet N. Scalisi, (2) and Gerald M. Reaven (1)* ((1) Stanford University School of Medicine, Department of Medicine, Stanford, CA 94305; (2) Atherotech, Birmingham, AL 35211; * address correspondence to this author at: Falk Cardiovascular Research Center, Stanford University Medical Center, Stanford, CA 94305; fax 650-725-1599, e-mail firstname.lastname@example.org)
Table 1. Lipoprotein concentrations in 44 healthy nondiabetic volunteers as measured by the VAP-II methodology. (a) SSPG <5.3 mmol/L SSPG >10.8 mmol/L Lipoprotein measurement (n = 23) (n = 21) P VAP-II direct measurements of cholesterol Total cholesterol 4.82 (0.16) 5.18 (0.21) 0.21 HDL-C 1.24 (0.08) 0.85 (0.05) <0.001 [VLDL.sub.1] + [2.sup.-C] 0.16 (0.02) 0.48 (0.10) <0.01 HDL-C subfractions HDL2-C 0.26 (0.03) 0.16 (0.00) <0.001 HDL3-C 0.98 (0.05) 0.73 (0.03) <0.001 TG-rich lipoproteins TG 1.08 (0.12) 2.54 (0.40) [VLDL.sub.3a] [3b.sup.-C] 0.21 (0.03) 0.36 (0.03) <0.001 IDL-C 0.39 (0.03) 0.49 (0.05) 0.02 Lp(a) Lp(a)-C 0.18 (0.02) 0.19 (0.04) 0.85 LDL-C LDL-C 3.24 (0.16) 3.44 (0.21) 0.39 ND-LDL-C 2.67 (0.13) 2.77 (0.18) 0.62 LDL maximum time, s 118 (1) 111 (1) <0.001 LDL pattern 13 A; 6 3 A; 1 <0.001 intermediate intermediate (A/B); 4 B (A/B); 17 B (a) All values are the mean (SE) in mmol/L unless otherwise noted.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Technical Briefs|
|Author:||Chu, James W.; Abbasi, Fahim; Kulkarni, Krishnaji R.; Lamendola, Cynthia; McLaughlin, Tracey L.; Sca|
|Date:||Jun 1, 2003|
|Previous Article:||Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods.|
|Next Article:||Utilization, reliability, and clinical impact of point-of-care testing during critical care transport: six years of experience.|